MMS

Did you know pharma companies fully integrating AI across operations could double profits by boosting revenue and cutting costs? These technologies are transforming clinical trials by automating workflows, enhancing predictive modeling, and leveraging big data to help Sponsors improve decision-making, boost patient outcomes, and simplify trial processes. Key trends driving this transformation: ✔️Artificial Intelligence (AI) and Machine Learning (ML) ✔️Big Data and Real-World Evidence (RWE) ✔️Cloud Computing and Data Warehousing ✔️Blockchain for Data Security and Integrity ✔️And More Read our latest blog to explore the full insights: https://hubs.li/Q02WXNrY0 #ClinicalResearch #DataManagement #AI #Biostatistics #Innovation

National Alzheimer’s Disease Awareness Month is officially underway, and since its inception, MMS has been deeply committed to advancing clinical research in neurology-focused therapeutic areas, including Alzheimer’s disease! Through teamwork and global resources focused on regulatory submissions, safety and risk management, and full-service biometrics, we support leading sponsors with groundbreaking research aimed at understanding and treating neurodegenerative diseases. Together, we can work towards better treatments and brighter outcomes for those impacted by Alzheimer’s. 🧠 Learn more about our therapeutic expertise here: https://hubs.li/Q02WNzg90 #Alzheimers #Neurology #DrugDevelopment

Happy Diwali from MMS! As we celebrate the Festival of Lights, we extend our warmest wishes to our colleagues, clients, and partners around the world, especially to our teams in Bangalore and Hyderabad. May this Diwali bring joy, prosperity, and new beginnings to all. At MMS, we’re lighting the way to a brighter future in clinical research through innovation, collaboration, and dedication. Wishing everyone a safe and joyous Diwali! ✨ #Diwali #India #OneMMS

Outsourcing QC tasks in regulatory and medical writing gives sponsors a competitive edge, as managing QC activities in-house can stretch resources thin! This diverts valuable time from medical writers who could be focusing on more complex tasks. Our latest blog article taps into several key advantages, including: 🔶 Cost-effectiveness and lower overhead costs 🔶 Scalability and flexibility during peak periods 🔶 Faster turnaround times 🔶 Domain expertise and knowledge of regulatory guidelines Minimize the risk of non-compliance and costly delays. Read our latest article for details: https://hubs.li/Q02Wg5Xz0 #QualityControl #MedicalWriting #Outsourcing #PharmaceuticalIndustry

From industry-firsts to well-researched indications, MMS brings a wealth of specialized knowledge across therapeutic areas to ensure that your drug development programs are supported by a team that truly understands the unique challenges and opportunities presented! We are proficient in a diverse range of therapeutic areas, including rare diseases, psychedelics, oncology, radiopharmaceuticals, central nervous system (CNS) disorders, and many others. Whether you are pioneering new treatments for rare diseases, exploring the potential of psychedelics, or developing groundbreaking oncology therapies, MMS can bring your program to life through comprehensive solutions that focus on the long-term health of your project. Review our therapeutic area expertise to understand how MMS can help you achieve your development goals across a variety of indications: https://hubs.li/Q02W5kdP0 #TherapeuticExcellence #DrugDevelopment #RareDiseases #Oncology #CNSDisorders #Psychedelics #PharmaSolutions #ClinicalResearch #CRO #DataDriven #MMS

This recognition speaks volumes! Our Quality Management System (QMS) is designed for precision, efficiency, and excellence to ensure that every audit exceeds expectations. See what this President has experienced: https://hubs.li/Q02VYrLr0 #QMS #ClinicalResearch #Pharma #OneMMS #SponsorsSay

Are you attending PHUSE EU Connect 2024 next month? This is the premier event where data science, statistical programming, and innovative technology unite to shape the future of clinical development. Our own EU-based Director of Global Statistical Programming James Zee will be attending to discuss key trends in the industry and share the considerable impact that MMS has made for sponsors in biometrics globally. Register for the event here, and message us if you’d like to connect with James: https://hubs.li/Q02VQ5wl0 #PHUSE

MMS is heading to Bay Area Biotech Workshop (BBSW) 2024! Will you be there? 🚀 Nimish Sidhpura, VP and Head of North America Sales at MMS, will be there, focused on discussing strategies to drive innovation in biotech and clinical research. If you're attending, send us a message here to connect: https://hubs.li/Q02VCpDW0 📅 When: October 24-25 📍 Where: Crowne Plaza Hotel, Foster City, CA Our biometrics and regulatory teams are dedicated to helping biotech and pharma companies streamline their drug development journey. Whether you’re in early-phase or preparing for submission, MMS provides strategic insights, efficient trial design, high-quality biometrics, and comprehensive regulatory support to streamline your data processes and enhance the insights from your trials. Let’s connect at #BBSW2024 and discuss how we can partner to make your next submission a success! #Biometrics #ClinicalTrials #DrugDevelopment #RegulatoryAffairs #Biotech #BayAreaBiotech

We’re excited to be at the 16th Annual Outsourcing in Clinical Trials New England conference, hosted by Arena International Events Group, today! Whether you’re interested in optimizing clinical operations, leveraging innovative technologies, or enhancing patient recruitment for rare diseases, MMS has the solutions you need. From regulatory submissions to full-service biometrics and safety risk management, we’re here to help drive success in your clinical trials. Let’s kick off the show with great conversations and innovation! Stop by booth 54, or view the event details here: https://hubs.li/Q02Vq_4v0 #ClinicalTrials #Outsourcing #Pharma #OCTNE

Today, Raina Agarwal will present our latest webinar: Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Reporting Trial Results Under Revised EU-CTIS Transparency Rules! Revised EU-CTIS transparency rules have significantly affected nearly every sponsor’s decision-making process regarding redaction and disclosure activities of clinical information. Sponsors are finding it difficult to prepare both internal and external stakeholders for the demands of this regulation, including: ✅ consistent authoring and messaging around endpoint reporting ✅ targeted redaction or anonymization of confidential information across submission documents throughout the life-cycle of the study ✅ use of the CTIS portal to manage evolving transparency requirements In this Expert Insights webinar, MMS will present its real-time experience working on EU-CTIS submissions. Join us at 11:00 AM ET today! Last-minute registration is still available here: https://hubs.li/Q02VfwC00 #OneMMS #DrugDevelopment #Transparency #CTIS #CCI #Pharma #EMA